Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
about
Vedolizumab for induction and maintenance of remission in Crohn’s diseaseImplementation of the simple endoscopic activity score in crohn's diseaseThe Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment ResponseInflammatory bowel disease associated neoplasia: A surgeon's perspectiveSystematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel diseaseAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialMucosal healing and deep remission: what does it mean?Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseOptimising monitoring in the management of Crohn's disease: a physician's perspectiveTreating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesEvolving Concepts in Phases I and II Drug Development for Crohn's Disease.Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Biologics in inflammatory bowel disease: what are the data?Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study.Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target.Measuring disease activity in Crohn's disease: what is currently available to the clinician.Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn's disease regardless of anti-tumor necrosis factor alpha treatmentSafety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysisIn vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseThe Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.Management of Musculoskeletal Manifestations in Inflammatory Bowel DiseaseInflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease.Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6.Crucial steps in the natural history of inflammatory bowel disease.Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model.Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factorsEndoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegolMucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis.Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseEfficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report.Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study.
P2860
Q24187571-FC8A5AA8-CF32-43DA-816B-AA697808F056Q26749323-3898A153-82B3-4964-B4D8-835E746713E2Q26773129-E12A342C-B25D-4132-B3F3-3506FE86FC7DQ26774592-8C5D9288-FBA3-4EDF-AF8F-F7DCD0BD6750Q26823547-449006F9-3952-43C9-AFA5-AE45AC039671Q26829488-05709865-D228-438D-8E8A-7AB43F7CC95EQ26852447-6E6BAB97-45C9-4B37-B1E1-413EF2B34FA7Q26866940-A85C6BF3-DF80-4E3E-BC66-F60952737F54Q27007083-DFB88753-2FFB-43EC-A116-20F0EE51D0E8Q27008246-63E8BB2F-9626-4442-8E2E-005B2DB44D1BQ28085134-BC6CA285-1D42-49E6-9FBB-2E27558CB767Q30248641-3A220F8E-ED60-43A1-9040-7C2E60CC01BDQ30679247-117E21B7-7A7D-45C9-9783-61269B8D7C36Q31017419-C3E471C7-F256-44AB-ABDE-F12594D4A0CCQ33562796-BB4CF384-167D-46B4-AB4A-E2197D4298EFQ33632574-71FB1EA2-0465-4CE1-AB56-7CFEA72758ECQ33656852-0BE19D3B-73F6-42ED-BE9F-CA2C65BBE6E0Q33668961-45C65A53-56F4-405A-A0EA-45D2074FD2AAQ33763285-8027F689-8F96-40AA-BDC5-4529BF521B21Q34388571-1BCAF024-E217-499F-8B8C-94FE6575A0C9Q34429618-B8570222-C0D7-49E9-85C2-B6A89779CE7BQ35052356-52E1F3C9-040C-4DF1-9BC5-5DE5D6CD700EQ35100867-EE2C2521-43B3-4DD5-BA23-8782CDBB4F11Q35213972-1860FAAC-1324-408A-ACA6-A55877090E6BQ35559305-4F4B65D5-E6DB-46BC-9CD0-C69CDCA8C0FBQ35634736-59C39470-C18F-4935-9A27-DC65E07A9E7EQ35773115-5DD5F92B-5AD4-4D52-8DB8-1E5DAFA6D43DQ35807983-AB0B3578-EDD4-4B39-B7F1-8E52118021B0Q36089928-C0AD0069-3DC5-46BB-8B45-B8BA772279D4Q36093753-3178121A-121B-467E-AC5E-D7604909EE51Q36144457-14B25BB5-E0B9-44DD-9CE0-7407532971F3Q36316869-78FBEC04-5226-4BF7-8D04-34E253C6B6CFQ36380315-372F6391-E3FA-4334-A4CE-F62861CF1CF7Q36550808-E185DF2C-968B-415C-8E43-068607F060D4Q36578893-381E63F4-9C50-4801-9476-D9E455406C02Q36879683-DDC67435-AADD-4A38-94CC-25FCE2272628Q36889586-FA4E2B48-062C-41D5-8F07-26A1E845808BQ37231860-E8E77D6E-A2F7-4536-884F-466C5BF1609DQ37474234-394B0203-D6D6-45EA-AAC1-653852349B3EQ37589559-1BCCF6DB-D623-4399-A501-7718B7190688
P2860
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@ast
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@en
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@nl
type
label
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@ast
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@en
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@nl
prefLabel
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@ast
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@en
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@nl
P2093
P50
P921
P1433
P1476
Adalimumab induces and maintai ...... e: data from the EXTEND trial.
@en
P2093
Andreas Lazar
Anne Camez
Ashish Kumar
Douglas C Wolf
EXTEND Investigators
Kathleen G Lomax
Paul F Pollack
Walter Reinisch
P304
1102-1111.e2
P356
10.1053/J.GASTRO.2012.01.035
P407
P50
P577
2012-02-08T00:00:00Z